Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Visual Field and Quality-of-Life Change in the Treatment for Advanced Glaucoma Study.

Ophthalmology·2026
Same author

Cannula detachment-a solution to a significant patient safety and health economic issue.

Eye (London, England)·2026
Same author

The endemic avoidable harm of cannula dislodgement.

Eye (London, England)·2025
Same author

Assessment of the level of harm resulting from glaucoma progression due to review delay.

Eye (London, England)·2025
Same author

Prevalence of cannula dislocation during cataract surgery: a survey.

Journal of cataract and refractive surgery·2025
Same author

Emerging perspectives in quality of life after trabeculectomy surgery.

Eye (London, England)·2025

Related Experiment Videos

Primary low-risk trabeculectomy augmented with low-dose mitomycin-C.

Amar Alwitry1, Asyia Abedin, Vick Patel

  • 1Eye, Ear, Nose and Throat Centre, Queens Medical Centre, Nottingham - UK.

European Journal of Ophthalmology
|November 3, 2009
PubMed
Summary
This summary is machine-generated.

Low-dose mitomycin-C (MMC) augmentation in primary trabeculectomy safely and effectively reduces intraocular pressure (IOP). This glaucoma surgery achieved an 83.1% success rate with minimal complications, reducing medication needs significantly.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Glaucoma Surgery
  • Surgical Outcomes

Background:

  • Trabeculectomy is a common surgical procedure for managing glaucoma.
  • Mitomycin-C (MMC) is frequently used to augment trabeculectomy to improve success rates.
  • Optimizing MMC dosage and application is crucial for balancing efficacy and safety.

Purpose of the Study:

  • To evaluate the outcomes of primary trabeculectomy augmented with a specific low-dose regimen of mitomycin-C (MMC).
  • To assess the safety and efficacy of 0.1 mg/mL MMC applied for 1 minute during primary trabeculectomy.
  • To determine the impact on intraocular pressure (IOP) and medication requirements.

Main Methods:

  • Retrospective review of case notes for patients undergoing primary trabeculectomy with MMC augmentation.
  • Inclusion criteria: 0.1 mg/mL MMC concentration, 1-minute application, first eye only, and at least 1-year follow-up.
  • Data collected included patient demographics, postoperative course, complications, interventions, and IOP outcomes.

Main Results:

  • Fifty-nine eyes met the inclusion criteria; mean follow-up was 19.3 months.
  • Bleb leaks occurred in 27.1% of cases, with only one requiring surgical revision.
  • Success (IOP < 16 mmHg without medication at 1 year) was achieved in 83.1% of cases, with mean IOP reducing from 23.1 to 13.5 mmHg (p<0.001).

Conclusions:

  • Primary trabeculectomy augmented with low-dose MMC (0.1 mg/mL for 1 minute) is a safe and effective IOP-lowering procedure.
  • This approach demonstrates a high success rate and a favorable safety profile for low-risk glaucoma patients.
  • Significant reduction in topical medication use was observed post-surgery.